The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Drug Hunter is already relied upon by researchers at more than 200 leading organizations, including Eli Lilly, Biogen, Merck KGaA, Isomorphic Labs, Deerfield Management
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Replicate will receive research funding and could potentially receive up to approximately US$550 million
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Subscribe To Our Newsletter & Stay Updated
